Roche Holdings Will Likely See Steady Earnings Growth Despite Loss Of Patents For Key Drugs

Roche Holdings (NASDAQ:RHHBY) recently posted its Q2 results, which were more or less in line with estimates. The company's overall revenues grew 7%, led by a continued ramp up in Ocrevus, and Perjeta sales. Ocrevus, which is a new drug, has seen strong demand of late, and marks the best launch...